Allergan, Dura to Co-Market Ophthalmic Products
The companies will co-launch Alocril (nedocromil sodium ophthalmic solution 2%), Allergan's proprietary topical compound indicated for the treatment of itch associated with allergic conjunctivitis, by March of this year. Allergan will promote Alocril to ophthalmologists; Dura will promote the product to primary care practitioners and respiratory specialists.
The agreement includes a joint structure to evaluate additional opportunities for Dura to promote specific development-stage products, once the above products are approved, and a commitment to launch a second product to the same segments at a yet unspecified date.
Allergan received United States Food and Drug Administration marketing approval for Alocril (nedocromil sodium ophthalmic solution 2%) in December 1999. Clinical studies demonstrated that the product provides effective treatment for itch due to allergic conjunctivitis. Alocril has been shown to inhibit mediator release from mast cells as well as decreasing chemotaxis and decreasing activation of other cell types. The drug's safety profile allows it to be used on children three years and older.
Allergan Inc. develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets.
Dura Pharmaceuticals Inc. is a developer and marketer of prescription pharmaceutical products for the treatment of allergies, asthma, pneumonia, and related respiratory conditions.
For more information: Cam L. Garner, Chairman and CEO, Dura Pharmaceuticals Inc., 7475 Lusk Blvd., San Diego, CA 92121. Tel: 858-457-2553. Fax: 858-457-2555. David E.I. Pyott, President and CEO, Allergan Inc., 2525 Dupont Dr., Irvine, CA 92612. Tel: 714-246-4500. Fax: 714-246-4971.